A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Clinical Trial Grant
Awarded By
Caribou Biosciences, Inc.
Start Date
December 7, 2023
End Date
November 30, 2028
Awarded By
Caribou Biosciences, Inc.
Start Date
December 7, 2023
End Date
November 30, 2028